Established therapies and novel targets in the treatment of Parkinson's disease

Livia Dézsi, L. Vécsei

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Parkinson's disease affects more than 1% of individuals older than 60 years of age. The gold standard of its symptomatic treatment is levodopa therapy, which in time leads to motor fluctuations and dyskinesia due to noncontinuous receptor stimulation. Dopamine agonists and monoamine oxidase-B inhibitors are recommended as initial therapy, but they are less effective in the advanced stages of the disease. Treatment should be individualized for the patient, dependent on the stage, with attention to nonmotor symptoms. No effective neuroprotective therapy for Parkinson's disease is yet available, and there is currently substantial interest in the development of new nondopaminergic agents. Analogs of kynurenic acid and inhibitors of the enzymes involved in the synthesis of quinolinic acid may exert a neuroprotective effect.

Original languageEnglish
Pages (from-to)631-644
Number of pages14
JournalExpert Review of Clinical Pharmacology
Volume2
Issue number6
DOIs
Publication statusPublished - 2009

Fingerprint

Parkinson Disease
Kynurenic Acid
Quinolinic Acid
Therapeutics
Monoamine Oxidase Inhibitors
Dopamine Agonists
Monoamine Oxidase
Dyskinesias
Levodopa
Neuroprotective Agents
Enzyme Inhibitors

Keywords

  • Continuous stimulation
  • Dopamine agonist
  • Dyskinesia
  • Kynurenines
  • Levodopa
  • MAO-B inhibitor
  • Parkinson's disease

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Established therapies and novel targets in the treatment of Parkinson's disease. / Dézsi, Livia; Vécsei, L.

In: Expert Review of Clinical Pharmacology, Vol. 2, No. 6, 2009, p. 631-644.

Research output: Contribution to journalArticle

@article{0ac2f48af27041ffb5fbb8239c383fa9,
title = "Established therapies and novel targets in the treatment of Parkinson's disease",
abstract = "Parkinson's disease affects more than 1{\%} of individuals older than 60 years of age. The gold standard of its symptomatic treatment is levodopa therapy, which in time leads to motor fluctuations and dyskinesia due to noncontinuous receptor stimulation. Dopamine agonists and monoamine oxidase-B inhibitors are recommended as initial therapy, but they are less effective in the advanced stages of the disease. Treatment should be individualized for the patient, dependent on the stage, with attention to nonmotor symptoms. No effective neuroprotective therapy for Parkinson's disease is yet available, and there is currently substantial interest in the development of new nondopaminergic agents. Analogs of kynurenic acid and inhibitors of the enzymes involved in the synthesis of quinolinic acid may exert a neuroprotective effect.",
keywords = "Continuous stimulation, Dopamine agonist, Dyskinesia, Kynurenines, Levodopa, MAO-B inhibitor, Parkinson's disease",
author = "Livia D{\'e}zsi and L. V{\'e}csei",
year = "2009",
doi = "10.1586/ecp.09.47",
language = "English",
volume = "2",
pages = "631--644",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Established therapies and novel targets in the treatment of Parkinson's disease

AU - Dézsi, Livia

AU - Vécsei, L.

PY - 2009

Y1 - 2009

N2 - Parkinson's disease affects more than 1% of individuals older than 60 years of age. The gold standard of its symptomatic treatment is levodopa therapy, which in time leads to motor fluctuations and dyskinesia due to noncontinuous receptor stimulation. Dopamine agonists and monoamine oxidase-B inhibitors are recommended as initial therapy, but they are less effective in the advanced stages of the disease. Treatment should be individualized for the patient, dependent on the stage, with attention to nonmotor symptoms. No effective neuroprotective therapy for Parkinson's disease is yet available, and there is currently substantial interest in the development of new nondopaminergic agents. Analogs of kynurenic acid and inhibitors of the enzymes involved in the synthesis of quinolinic acid may exert a neuroprotective effect.

AB - Parkinson's disease affects more than 1% of individuals older than 60 years of age. The gold standard of its symptomatic treatment is levodopa therapy, which in time leads to motor fluctuations and dyskinesia due to noncontinuous receptor stimulation. Dopamine agonists and monoamine oxidase-B inhibitors are recommended as initial therapy, but they are less effective in the advanced stages of the disease. Treatment should be individualized for the patient, dependent on the stage, with attention to nonmotor symptoms. No effective neuroprotective therapy for Parkinson's disease is yet available, and there is currently substantial interest in the development of new nondopaminergic agents. Analogs of kynurenic acid and inhibitors of the enzymes involved in the synthesis of quinolinic acid may exert a neuroprotective effect.

KW - Continuous stimulation

KW - Dopamine agonist

KW - Dyskinesia

KW - Kynurenines

KW - Levodopa

KW - MAO-B inhibitor

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=70549096887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70549096887&partnerID=8YFLogxK

U2 - 10.1586/ecp.09.47

DO - 10.1586/ecp.09.47

M3 - Article

C2 - 22112257

AN - SCOPUS:70549096887

VL - 2

SP - 631

EP - 644

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 6

ER -